Comorbidity Burden Is Associated With Increased Adverse Events, DMT Discontinuation in MS Clinical Trials

Data from more than 16,000 trial participants point to possible challenges with assessing and safely administering novel therapeutics among those with comorbidities—which may be present in as much as half of the patient population.:

Source: Neurology Read More